IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

Established in 2010, Curis Lifesciences Limited is a pharmaceutical company specializing in the development, manufacturing, and distribution of a diverse range of products.The company manufactures pharmaceutical products both internationally and nationally on a loan license or on a contract basis, and for own brand marketing.The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.Curis Lifesciences specializes in the development, manufacturing, and distribution of a broad array of pharmaceutical products that include:General pharmaceutical tablets and capsulesOral liquidsExternal preparationsSterile ophthalmic ointmentsThe firm has a state-of-the-art manufacturing facility in Sanand, Gujarat, operating under strict quality control measures to ensure the safety and efficacy of its products.The company offers different pharmaceutical formulations and products made on a contract basis.They provide tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments. As of June 30, 2024, the company has 93 permanent employees.
Revenue Growth
Sotefin Bharat
| Companies Name | Open - Close | Issue Size | Min. Qty | Issue Price | Apply |
|---|---|---|---|---|---|
Sotefin Bharat SME | 16th Jul 2026 - 20th Jul 2026 | 89.76 Cr | 600 Shares | ₹ 178.00 | |
Caliber Mining & Logistics Mainboard | 17th Jul 2026 - 21st Jul 2026 | 450.00 Cr | 35 Shares | ₹ 402.00 |
Open Date
07 Nov 2025
Close Date
11 Nov 2025
Min Investment
₹256000
Lot Size
2000 Shares
Issue Size
₹27.52 Cr
Price Range
₹120 - ₹128
Listing Date
Nov 14, 2025
IPO Doc
RHP PDFCompany Valuation
Earning Expansion
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.
₹2.44 crore for manufacturing facility upgrades and ₹3.62 crore for storage facility construction. The company will use ₹1.86 crore towards repayment of outstanding secured loans. ₹2.69 crore will be used towards product registrations in other countries Curis Lifesciences will use ₹11.25 crore to fund working capital requirements. Part of the IPO proceeds will be used for general corporate purposes
Capital Expenditure
22.02%
Repayment of loans
6.76%
Product registrations
9.77%
Working capital
40.87%
General corporate purposes
20.65%
₹2.44 crore for manufacturing facility upgrades and ₹3.62 crore for storage facility construction.
The company will use ₹1.86 crore towards repayment of outstanding secured loans.
₹2.69 crore will be used towards product registrations in other countries
Curis Lifesciences will use ₹11.25 crore to fund working capital requirements.
Part of the IPO proceeds will be used for general corporate purposes
Times subscribed by category (bars capped at 10x for readability). Dashed line marks 1.0x (fully subscribed).
In Cr.
| Key Performance Indicator | 31-Dec-24 (In Cr.) | 31-Mar-24 (In Cr.) | 31-Mar-23 (In Cr.) | 31-Mar-22 (In Cr.) |
|---|---|---|---|---|
| Revenue | 36.91 | 35.89 | 36.39 | 23.76 |
| EBITDA | 8.89 | 8.41 | 3.25 | 3.58 |
| Expenses | ||||
| Profit After Tax | 5.30 | 5.03 | 1.85 | 0.49 |
| Assets | 50.12 | 33.82 | 29.67 | 27.40 |
| Net Worth | 15.53 | 5.97 | 0.95 | 0.90 |
| Reserves | 9.59 | 5.47 | 0.45 | -1.40 |
| Borrowing | 16.16 | 17.09 | 16.19 | 17.62 |
Curis Lifesciences
Dharmesh Dashrathbhai Patel Mr
Siddhant Jayantibhai Pawasia Mr
Piyush Gordhanbhai Antala Mr
N/A
N/A
MUFG Intime India Pvt.Ltd.
PF-23, GIDC Sanand - II, Industrial Estate, Sanand, Ahmedabad, Gujarat, 382110